As regulatory expectations for cell therapy manufacturing continue to rise, PAI readiness must be built into everyday operations rather than undertaken as a checklist initiative. Inspection readiness is embedded across Kincell Bio’s quality systems, manufacturing practices, and organizational culture. By aligning process development, analytics, and GMP operations with regulatory expectations from the outset, we help sponsors minimize risk, strengthen filings, and move confidently toward approvals and, ultimately, reliable commercial supply.
Being PAI-ready every day means embedding inspection-grade quality into daily operations rather than preparing for inspections only as they approach. This mindset is built into every process, from CMC development and analytical readiness to manufacturing execution and documentation practices. Regulatory requirements are mapped directly to policies, procedures, and training, ensuring traceability, data integrity, and process control. Our teams operate under the understanding that every batch, record, and decision must meet regulatory expectations, creating a culture where quality, accountability, and patient safety guide all our efforts.
We build PAI readiness into daily operations through a structured, proactive approach that aligns quality systems, manufacturing practices, and regulatory expectations from the outset. Key elements of our program include:
A structured, proactive approach to regulatory mapping catalogs all applicable regulations, guidance documents, and internal policies into a comprehensive framework that supports gap assessment, risk scoring, and documentation readiness. This systematic approach ensures that quality systems, SOPs, and processes are continuously tracked and refined, keeping programs inspection-ready at every stage of development.
Kincell provides support across the full cell therapy lifecycle, with our Gainesville, FL, USA facility focused on early CMC and clinical supply, and our Research Triangle Park, NC, USA facility emphasizing pivotal and commercial manufacturing. Together, the two facilities provide scalable and redundant GMP capacity, robust analytics, and expansion-ready infrastructure to ensure long-term program continuity and supply reliability.
Kincell Bio develops and delivers tomorrow’s cell therapy cures by integrating comprehensive, end-to-end capabilities across the full product lifecycle, with deep expertise spanning a broad range of autologous and allogeneic cell therapy modalities.
Integrated Services
In our new eBook, Navigating Intensifying Cell Therapy Regulatory Expectations, Kincell Bio’s scientific and executive leadership break down what’s changed, why programs...
As the cell therapy sector continues to mature, regulatory expectations are rising. Deviation and change control management are now table stakes, and...
At Kincell Bio, quality isn’t a checkpoint; it’s a mindset. In our latest video, leaders and team members across our RTP facility...
Talk to an expert
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields
